EpiPen: A Case Study in Health Insurance Failure
September 15, 2016
Senior Fellow John R. Graham writes at NCPA's Health Blog:
I recently wrote a post describing EpiPen as a "Case Study in Government Harm," describing how the government had made it possible for the manufacturer to increase prices of the life-saving drug multiple times without fear of retaliation. It is also a case study in how health insurance distorts our choices and increases their cost. I learned this by following an Internet advertisement for EpiPen down its rabbit hole.
The ad induced me to download my "EpiPen Savings Card" which would ensure I paid nothing for my EpiPens (up to six, according to the ad):
Browse more articles on Health Issues